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ABSTRACT
Cancer immunotherapy has been shown to enhance established treatment 
regimens. We evaluated the potential reinforcing effect of IL-15 in trastuzumab treated 
humanized tumor mice (HTM) which were generated by concurrent transplantation 
of neonatal NOD-scid IL2Rγnull mice with human hematopoietic stem cells (HSC) 
and HER2 positive breast cancer cells (metastasizing SK-BR-3, solid tumor forming 
BT474).
We found that trastuzumab treatment efficacy mainly depends on the immediate 
anti-tumorigenic cellular effect which is significantly enhanced by tumor interacting 
immune cells upon cotransplantion of HSC. However, trastuzumab treatment caused 
elevated CD44 expression on tumor cells that metastasized into the lung and liver 
but did not hinder tumor cell dissemination into the bone marrow. Moreover, in a 
number of SK-BR-3-transplanted animals disseminated CD44high/CD24low tumor cells 
lost trastuzumab sensitivity. Concerning the FcγRIIIa polymorphism, trastuzumab 
treatment efficiency in HTM was higher in mice with NK-cells harboring the high 
affinity FcγRIIIa compared to those with low affinity FcγRIIIa. In contrast, IL-
15 caused the strongest NK-cell activation in heterozygous low affinity FcγRIIIa 
animals. Although IL-15 enhanced the trastuzumab mediated tumor defense, an 
unspecific immune stimulation resulted in preterm animal death due to systemic 
inflammation. Overall, treatment studies based on “patient-like” HTM revealed 
critical and adverse immune-related mechanisms which must be managed prior to 
clinical testing.
INTRODUCTION
Antigen-specific antibodies are the primary tool for 
individualized treatment of cancer patients. Specific tumor 
targeting has a high curative potential and is typically 
associated with less systemic side effects compared to 
cytotoxic treatment regimens. The treatment of early and 
advanced HER2-positive breast cancer (BC) patients 
with trastuzumab (Herceptin®), a humanized monoclonal 
anti-HER2 antibody, results in both prolonged disease-
free and overall survival (DFS, OS). However, >50% of 
HER2-positive patients do not benefit due to of de-novo 
or acquired resistance [1]. On the one hand, however, 
therapy failure has been attributed to cellular effects (e.g., 
inefficient trastuzumab binding or activation of alternate 
signaling pathways). On the other hand there is apparently 
an insufficient activation of immune effector cells, e.g., 
NK-cells and macrophages, which are thought to exert 
antibody-dependent cellular cytotoxicity (ADCC) [1].
The potential impact of an ADCC-related immune 
defense triggered by trastuzumab has been discussed 
controversially for many years. For example, Clynes et 
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al. reported increased tumor growth in FcgRIII knock 
down mice [2]. Barock and colleagues demonstrated loss 
of function in trastuzumab-Fab compared to the native Fc 
containing immunoglobuline [3]. Moreover, a delayed 
progression of trastuzumab-treated BC disease has 
been linked to increased NK-cell tumor infiltration and 
enhanced ADCC [4-7]. In contrast to the aforementioned 
findings the therapeutic expansion and activation of NK-
cells in patients by IL-2 administration did not enhance 
immunological tumor defense or improve outcome [8]. 
Other clinical studies revealed a beneficial effect of ADCC 
only in a monotherapeutic treatment setting but not in 
combination with chemotherapy [9]. However, Petricevic 
et al. reported that efficacy of trastuzumab-specific 
ADCC was not affected by treatment duration, disease 
progression or concomitant chemotherapy [10]. Overall, 
the impact of trastuzumab-triggered ADCC on therapy 
success in BC patients remains unclear.
Nevertheless, the presence of tumor infiltrating 
lymphocytes (TILs), which include T- NK- and other 
cells, has been associated with a favorable outcome in 
HER2-positive (and triple negative) BC patients [11-12], 
although, tumor cells develop a variety of mechanisms to 
avoid immune defense. A number of escape mechanisms 
are known to affect NK-cell activity, e.g., the secretion 
of immunosuppressive cytokines (e.g. TGFb) [13], 
the induction of regulatory T- [14] or myeloid derived 
suppressor cells (MDSC) [15], the expression of 
programmed death ligand-1 (PDL-1) [16] or first apoptosis 
signal (FAS) ligand [17], the induction of Indolamin-2,3-
Dioxygenase (IDO) [18], and the secretion of soluble 
MHC class I chain-related (MIC) molecules MICA/B [19].
Thus, a potential approach to overcome the 
immunosuppressive activity of tumor cells is cytokine-
mediated immune (especially T- and NK-) cell activation. 
IL-15 is known to stimulate NK-cells both in-vitro [20] 
and in-vivo [21-23]. The therapeutic potency of IL-15 in 
advanced melanoma and renal cell cancer patients [24] 
has been investigated in previous clinical trials. However, 
side effects which were not recognized in previous clinical 
studies performed in primates (rhesus macaque) [25], 
forced dosage reduction. Subsequently, investigations 
based on recombinant human IL-15 (rhIL-15) and IL-15 
receptor complex (IL15Rα) have been initiated to evaluate 
the maximum-tolerated dose and an efficient application 
route. The results of these studies, however, are still 
pending.
In this context, we assessed the therapeutic 
efficiency of IL-15 to boost the therapeutic activity 
of trastuzumab in HTM, which were generated by the 
cotransplantation of HSCs and HER2-positive BT474 and 
SK-BR-3 BC cells into neonatal immunodeficient NSG 
mice which resulted in two different HTM models: The 
transplantation of only moderately trastuzumab sensitive 
SK-BR-3 cells results in an ascitis with greater incidence 
of metastases in different organs including the brain. In 
contrast highly trastuzumab sensitive BT474 cells form 
a solid tumor growth upon transplantation with fewer 
metastases and no dissemination into the brain. Based on 
these different HTM models, we investigated the immune 
response, the importance of FcgRIIIa polymorphism, 
and the adaptation processes of the tumor cells during 
trastuzumab and IL-15 treatment.
RESULTS
Trastuzumab treatment prolongs DFS and OS in 
BT474 but not in SK-BR-3-based HTM
Upon the simultaneous transplantation of human 
CD34+ hematopoietic stem cells (HSC) and human BC 
cell lines (BT474 and SK-BR-3), the NSG mice developed 
liver-associated tumor growth (BT474; Figure 1A-I) or 
tumor cell effusion in the peritoneal cavity (SK-BR-3). 
IHC verified the preservation of HER2 over-expression in 
the originally transplanted tumor cells (Figure 1A-II). The 
amount of human reconstitution (% human immune cells) 
in both models was similar (Figure 1A-III) and therefore 
independent of the co-transplanted tumor cell line (BT474 
spleen: 63 +/-4 SEM; BT474 bone marrow (bm): 52 +/- 4; 
SK-BR-3 spleen: 57+/- 4, SK-BR-3 bm: 47+/-4). Further 
analyses of cell subsets revealed an increased proportion of 
B cells in the spleen of SK-BR-3 (Supplementary Figure 
S1A; average age 16 weeks post transplant) compared to 
BT474 transplanted mice (Supplementary Figure S1B; 
average age 23 weeks post transplant) which is due to 
the different time point of analyses. The courses of T-cell 
(increase over time) and B-cell (decrease) fraction sizes 
over time were monitored in all HTM (Supplementary 
Figure S1C). The overall percentage of human immune 
cells (CD45) and the myeloid cell (CD33) fraction 
remained considerable stable within 10 - 43 weeks of the 
animals’ life time (Supplementary Figure S1C). Tumors 
were detectable in BT474 and SK-BR-3 transplanted 
animals sacrificed 10 weeks post transplant.
To investigate the impact of trastuzumab on 
solid tumor growth, BT474 transplanted NSG mice 
were treated once a week and the OS of the animals 
was evaluated (Figure 1B). The OS of HTM was 
significantly prolonged by the trastuzumab treatment 
(Figure 1B; p=0.0068), whereas the trastuzumab-treated 
TM without a human immune system did not reach a 
statistically significant survival benefit (Figure 1C; 
p=0.1513). The histological examination also revealed 
reduced lung metastatic diseases in HTM but not in TM 
(Table 1A), reflecting the metastasis-impairing effect 
of the human immune system. However, the DFS was 
prolonged by trastuzumab treatment both in the presence 
(HTM; Figure 1D) and absence (TM; Figure 1E) of the 
immune system. Since SK-BR-3 cells were isolated 
from a patient’s effusion, these cells recapitulate their 
original growth behavior in the form of a peritoneal 
Oncotarget2733www.impactjournals.com/oncotarget
Figure 1: The overall and tumor-free survival in BT474- and SK-BR-3-transplanted tumor mice is differently 
influenced by anti HER2 (trastuzumab) treatment. (A-1) BT474-transplanted HTM develop liver-associated tumors with HER2 
over expression (A-II) Scale bar represents 100 µm. Flow cytometric analyses reveal an equivalent percentage of human engraftment (% 
CD45+ cells) in the spleen and bone marrow (bm) of SK-BR-3- and BT474-transplanted HTM (A-III) The number of animals included in 
each analysis is mentioned above each bar. Illustration of overall survival (OS) and tumor-free survival (TFS) of BT474-transplanted HTM 
(B, D) and TM (C, E) and SK-BR-3-transplanted HTM (F, H) and TM (G, H) respectively. Significance was calculated using the Log-rank 
(Mantel-Cox) test, and the number of analyzed animals is indicated in brackets.
Table 1: Immunohistological assessment of metastases in trastuzumab-treated and non-treated (control) HTM and TM 
A. BT474
HTM control HTM + trast p-value (control 
versus trast)
TM control TM + trast p-value (control 
versus trast)
lung 10/19 1/12 0.0201 4/8 3/11 0.3765
liver 6/13 1/3 1 4/10 2/8 0.6380
spleen 2/17 0/11 0.5053 0/6 0/8 1
brain 0/10 0/9 1 1/4 0/8 0.3333
B. SK-BR-3
HTM control HTM + trast p-value (control 
versus trast)
TM control TM + trast p-value (control 
versus trast)
Lung 13/14 8/8 1 11/11 4/4 1
Liver 7/12 7/8 0.3246 9/11 3/3 1
spleen 6/11 3/5 1 9/11 4/4 1
brain 5/5 0/3 0.0179 7/8 1/1 1
BT474 (A) and SK-BR-3 (B) transplanted HTM and TM were immunohistologically stained using anti-HER2 antibodies 
in the lung, liver, spleen and brain. The number of animals with detectable HER2+ metastasis of the total number of 
animals (n/n) is indicated. Statistical differences were calculated using the two-sided Fisher’s exact test and significant 
differences are marked in bold.
Oncotarget2734www.impactjournals.com/oncotarget
-located ascites in NSG mice. The development of 
ascites accompanies cell metastasis into different organs 
including the brain and bm. Remarkably, trastuzumab 
treatment of SK-BR-3-transplanted mice does not 
improve either the OS (Figure 1F & 1G) or DFS (Figure 
1H) of these animals. Apparently, there is no efficient 
immune cell activity to compensate for trastuzumab 
inefficacy, although reduced brain metastasis could 
be observed in humanized SK-BR-3-based HTM 
(p=0.0179) but not in TM (p=1; Table 1B).
Adjuvant IL-15 administration in combination 
with trastuzumab diminishes tumor burden but 
also reduces DFS and OS in BT474 and SK-BR-3 
HTM
HTM received the potent IL-15/IL-15Rα 
complex every two weeks. Unexpectedly, the systemic 
administration of IL-15 in combination with trastuzumab 
caused a significant reduction in OS in both the BT474- 
(Figure 2A) and SK-BR-3- (Figure 2B) based HTM model. 
The DFS was not reduced in BT474 HTM (Figure 2C) but 
was reduced in SK-BR-3 HTM (Figure 2D). In BT474 
HTM, the tumor volume in tumor-bearing animals shrank 
from 3416 mm3 (+/- 1401, n=12) in control mice to 2800 
mm3 (+/- 932; n=5) in trastuzumab-treated animals down 
to 192 mm3 (+/- 186; n=4) in IL-15/trastuzumab-treated 
mice (Figure 2E). Similarly, 50% (4/8) of the treated SK-
BR-3 HTM had no, or only a very low level of tumor 
burden left in the peritoneum upon IL-15/trastuzumab 
treatment (Figure 2F), whereas trastuzumab therapy alone 
was not sufficient to reduce the amount of tumor cells in 
any of the treated mice. In addition, the tumor burden in 
the lung of IL-15/trastuzumab-treated mice tended to be 
lower compared to control or trastuzumab-treated HTM 
(Supplementary Figure S2A & S2B).
The considerably reduced OS in both xenograft 
types (primary solid tumor growth and primary 
effusion) strictly correlates with (i) an immune cell 
depletion observed in the bm (Figure 3A & 3B), (ii) 
with a splenomegaly (Figure 3C), and (iii) with immune 
cell invasion into various organs (Figure 3D; liver 
exemplarily shown). Moreover, the liver (Figure 3E) and 
lung infiltrating leucocytes highly expressed CD44, thus 
indicating their activation and capacity for recirculation 
and homing. CD44-positive leucocytes were also found 
in the spleen of non-treated control HTM but were 
not detectable in the tumor or liver of these animals 
(Supplementary Figure S3). In trastuzumab-treated 
HTM, CD44 expression was triggered in leucocytes 
Figure 2: IL-15 immunostimulation influences the outcome of trastuzumab treatment in HTM. Graphs represent the OS 
and TFS in BT474 (A, C) and SK-BR-3 (B, D) transplanted HTM treated with trastuzumab +/- IL-15. Significance was calculated with the 
Log-rank (Mantel-Cox) test. (E) Tumor volume of treated and untreated BT474 HTM. Significance was calculated with Tukey’s multiple 
comparisons test (*=p<0.05). (F) Tumor cell burden was counted in SK-BR-3-transplanted HTM in the peritoneum (ascitis) of the animals. 
HTM with low or no tumor cell count are marked with a red circle.
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located in the spleen but it was only rarely visible in the 
tumor tissue or in other organs (e.g. liver; Supplementary 
Figure S3). CD44 expression in IL-15/trastuzumab 
treated HTM was increased in spleen, tumor, and liver 
(Supplementary Figure S3).
Moreover, IL-15 treatment significantly 
stimulated a human immune cell infiltration into the 
tumor cell loaded peritoneum of SK-BR-3 HTM (Figure 
4A). Advanced flow cytometric analysis revealed that 
the main population of invasive immune cells belonged 
to the CD3+ T-cell subset (Figure 4B). Particularly 
tumor-free HTM (red symbols) showed an increased 
T-cell infiltration but also enhanced NK- and myeloid 
cell influx (Figure 4B). The main population of TILs in 
solid tumors consisted of CD4 T-cells in both mouse 
models (Figure 4D exemplarily shown for SK-BR-3 
HTM). Notably, HTM without detectable solid tumor 
formation (BT474, red symbols) at the end of the 
experiments showed a tendency towards a higher CD4 
T-cell fraction in the spleen compared to tumor-bearing 
mice (Figure 4C).
CD44 expression in tumor cells is caused by 
trastuzumab treatment in-vivo and is increased 
in trastuzumab-resistant disseminated tumor 
cells isolated from the bm
The CD44, CD24, HER2, and epithelial cell 
adhesion molecule (EpCAM) expression on BT474 and 
SK-BR-3 tumor cells was assessed by flow cytometry 
as a function of tumor treatment (Supplementary Figure 
S4A). We found a significantly increased CD44 expression 
on metastasized tumor cells in the lung and the liver of 
HTM and TM with trastuzumab treatment (Supplementary 
Figure S4B). However, the EpCAM (data not shown) and 
CD24 expression (Supplementary Figure S4C) was not 
altered. Tumor cells isolated from ascites (i.e., peritoneal 
tumor cells, PTC) did not show a significant change in any 
of the tested markers (Supplementary Figure S4B & S4C).
Cancer metastasis is the main cause of cancer-
related death and disseminated tumor cells (DTCs), 
preferably homing in the bm niche, are considered to be 
the major source of metastasis. To characterize DTCs in 
the bm of HTM, single cells from the bm aspirates were 
expanded ex-vivo (Figure 5A; HTM: 13.3 weeks +/- 1.5, 
n=17; TM: 10.1 +/- 1.2, n=18) and subsequently analyzed 
by flow cytometry. The propagation of bm-derived DTCs 
was more successful in samples derived from SK-BR-3-
transplanted mice than from BT474-transplanted mice 
(Table 2). The cell propagation was not affected by the 
presence of immune cells (HTM versus TM; BT474: p = 
1; SK-BR-3: p = 0.16; two-sided Fisher’s exact test) or by 
exposure to trastuzumab (Table 2; BT474: p = 1 (HTM & 
TM); SK-BR-3: p = 0.7 (HTM) & 0.6 (TM)). Combined 
trastuzumab/IL-15 treatment tended to reduce the 
number of successful ex-vivo DTC cultures. In addition, 
we assessed the fraction of proliferating SK-BR-3 cells 
(S-phase fraction, SPF) derived from HTM and TM bm 
Figure 3: Side effects induced by IL-15 treatment in HTM. Bone marrow (bm) cell counts from femur of BT474 (A) and SK-
BR-3 (B) transplanted HTM are illustrated. Significance was calculated using the One-way Anova (A**, A***) and Tukey’s multiple 
comparison test (*=p<0.05; **=p<0.01; ***=p<0.001). (C) Image of a splenomegalie of an IL-15-treated HTM (right spleen) compared to 
an untreated HTM (left spleen). (D+E) Immunohistological staining of lymphocyte population in the liver of an IL-15-treated HTM (CD4 
= T helper cells; CD8 = cytotoxic T-cells, CD79A = B-cells; CD68 = macrophages; CD44 = activated T-cells). Bars represent 100 µm.
Oncotarget2736www.impactjournals.com/oncotarget
Figure 4: Tumor infiltrating lymphocytes are increased after IL-15 stimulation. Graphs represents the percentage of human 
leucocytes (%CD45; A) and the immune subpopulations (T-cells (CD3), B-cells (CD19), myeloid cells (CD33), and NK-cells (Nkp46)) 
in the peritoneal exudate cells (PEC; A, B). Red symbols represent HTM without and blue symbols represent HTM with few remaining 
tumor cells in the peritoneum. Significance (*=p<0.05; ***=p<0.001; ****=p<0.0001) was calculated using Tukey’s multiple comparison 
test (A) and Bonferoni’s multiple comparison test (B+C) and values were included in the graphs when p was below 0.5. (C) Graphs 
summarize CD4 and CD8 distribution in the spleen of BT474 HTM. Red symbols represent HTM without detectable tumors at the end of 
the experiments. (D) Immunohistological staining of HER2, CD4 and CD8 in a tumor sample of SK-BR-3-transplanted and IL-15-treated 
HTM. Bars represent 100 µm.
aspirates with or without trastuzumab treatment. A flow 
cytometric DNA profile of resistant cells is presented in 
Figure 5B. A total of 5 trastuzumab insensitive bm cultures 
were obtained from SK-BR-3 cell transplanted TM (n = 4) 
and HTM (n = 1) in both treated and untreated animals 
(Figure 5C). Cumulatively, the reduced sensitivity is more 
pronounced in samples derived from TM than from HTM 
(Figure 5D). This observation is independent of treatment 
regimen.
Different bone marrow cultures were phenotyped for 
HER2, CD24, CD44, and EpCAM (presented in Figure 
5E). Notably, all tested resistant cell samples showed 
enhanced CD44 and reduced CD24 expression (red 
symbols, Figure 5F). 6/16 bm aspirates derived from TM 
remained sensitive to trastuzumab treatment in spite of an 
elevated CD44 expression.
FcgRIIIa polymorphism affects the in-vivo 
treatment efficiency of trastuzumab both in the 
presence and absence of IL-15 in HTM
Low and high binding affinity of IgGs to FcgRIIIa 
is due to a receptor polymorphism, which is supposed to 
be involved in enhanced or poor NK-cell activation by 
therapeutic antibodies. Therefore, we analyzed the most 
common genotypes (homozygous low affinity (F/F) and 
the heterozygous F/V (low/high affinity) in HTM.
OS of both BT474- and SK-BR-3-based HTM 
was significantly prolonged by trastuzumab treatment 
independent of the FcgRIIIa genotype, whereas the DFS 
was only extended in mice transplanted with heterozygous 
(V/F) high affinity CD34+ HSC (Figure 6A). This 
pronounced responsiveness of the V/F bearing group 
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is also reflected by the significantly increased NK-cell 
number (in between V/F control and trastuzumab; between 
trastuzumab V/F and trastuzumab V/V; Figure 6B). In 
addition, CD16 expression was significantly increased 
in the trastuzumab-treated high affinity (V/F) versus low 
affinity (F/F) FcgRIIIa genotype (Figure 6C). However, 
the expression of other NK-cell-related differentiation 
markers (CD27, CD56, Figure 6D/data not shown) and the 
distribution of NK-cell subpopulations (effector/regulatory 
subsets, Figure 6E & 6F) do not depend on the FcgRIIIa 
genotype. Nevertheless, the CD56+CD27- phenotype 
represents the majority of NK-cells in the spleen (Figure 
6F).
IL-15 stimulation reduced the OS in the presence of 
both the low and high affinity FcgRIIIa variant. This effect 
is even more pronounced when low affinity FcgRIIIa 
receptors (F/F) are expressed (Figure 7A). The DFS was 
not significantly affected by the IL-15 treatment or by the 
FcgRIIIa genotype (Figure 7B). The unfavorable effect of 
IL-15 treatment on OS in the heterozygous low affinity 
group (Figure 7A) was associated with an increased NK-
cell number in the spleen and the liver of HTM (Figure 
7C). Additionally, the CD27 expression in NK-cells was 
significantly reduced (Figure 7D). An association between 
a CD27 loss and an increased cytotoxic T-effector and 
NK-cell function has been previously reported [26-27]. 
The expression of CD16 and CD56 on NK-cells and 
the distribution of NK-cell subpopulations (effector/
regulatory subsets) was independent from the FcgRIIIa 
genotype (data not shown). Notably, tumor eradication in 
HTM was observed in the presence of both the low and 
high FcgRIIIa genotype (SK-BR-3: n = 3 F/F, n = 1 V/F; 
BT474: n = 5 V/F, n = 1 F/F).
Figure 5: Trastuzumab resistance in ex vivo expanded DTC from the bone marrow is associated with increased CD44 
expression in SK-BR-3-transplanted NSG. (A) SK-BR-3-expanded DTC cell cultures extracted from femur and tibia (stained with 
anti-HER2; scale bar represents 100 µm) were incubated in the presence or absence of trastuzumab for 48 hours. The S-phase fraction 
(SPF, grey) of treated and untreated cultures did not significantly differ and is presented in Figure 5 (B) (30% vs. 32%). A collection of all 
data is illustrated in Figure 5 (C) and summarized for HTM and TM (independent of treatment) in (D, E) Exemplary histograms of HER2, 
CD24, EpCAM, and CD44 expression of the isotype (grey), SK-BR-3 cell culture (black) and one trastuzumab insensitive bone marrow 
(bm) culture (red) are shown. (F) Mean fluorescence intensity (MFI) of CD44 and CD24 expression in HER2+ tumor cells from ex-vivo 
expanded bm cultures are illustrated in the graphs. Symbols related to trastuzumab insensitive animals who were also analyzed for CD44 & 
CD24 expression, are displayed in red (C&E). Resistant cells without corresponding CD44/CD24 data are marked in blue. No significant 
differences were detectable in C & F using Tukey’s multiple comparison test. Statistical differences were calculated using the two-tailed 
unpaired t test in D (p = 0.0329).
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Figure 6: Influence of the FcgRIIIA genotype on NK-cell population and the overall outcome in trastuzumab-treated 
HTM. (A) Illustration of OS and DFS of BT474 and SK-BR-3-transplanted HTM dependent on the hetero (V/F) or homozygous (F/F) 
low affinity FcgRIIIA genotype. Numbers of analyzed animals are indicated in brackets. Significance was calculated using the Log-rank 
(Mantel-Cox) test. Flow cytometric analyses of the overall percentage (B) and the percentage of CD16 expression C) of NK-cells (Nkp46+) 
in the spleen, bone marrow (bm), lung and liver of treated and untreated HTM. Exemplary density plots of Nkp46 sub population expression 
CD16, CD56, and CD27 are shown in (D) and are summarized for all animals in (E & F) Differences were calculated using one-way 
(F) and two-way Anova (A**** = p <0.0001, A*** = p <0.001) and Tukey’s multiple comparison test (* *= p <0.01; *** = p <0.001; 
**** = p <0.0001; B, C, D) and values were included in the graphs when p was below 0.5. Bars represent the mean +/- SEM and each 
symbol represents one single animal.
Table 2: Rate of ex-vivo propagated DTCs derived from the bm of BT474 and SK-BR-3-transplanted HTM and TM 
treatment/mice No treatment 
(control)
Trastuzumab 
(+trast)
p-value  
(control versus trast)
Trastuzumab +IL-
15 (trast/IL-15)
p-value  
(trast versus trast/IL-15)
HTM BT474 4/19 (21 %) 3/14 (21%) 1 0/4 (0%) 1
TM BT474 2/9 (22%) 1/7 (14%) 1 --- --
HTM SK-BR-3 12/20 (60%) 10/14 (71%) 0.7170 3/8 (38%) 0.1870
TM SK-BR-3 16/19 (84%) 9/12 (75%) 0.6526 --- --
Single cells isolated from both femurs of BT474 and SK-BR-3-transplanted HTM and TM were cultured to expand 
DTC. The number of animals with successfully expanded DTC cultures of all tested samples (n/n) is indicated. Statistical 
differences were calculated using the two-sided Fisher’s exact test.
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DISCUSSION
Although trastuzumab significantly improves the 
overall outcome of BC patients, a significant fraction 
of patients suffer from de-novo or acquired resistance. 
Immune evasion of cancer cells is considered to be a 
major mechanism that accounts for therapy failure, 
even in antibody-treated patients. Here, we investigated 
the treatment efficiency of trastuzumab alone and in 
combination with IL-15 in HER2-positive BC-based 
HTM. Upon cotransplantation of HSCs and BC cells, 
the mice concurrently develop a human immune 
system and human tumor growth [23]. Thus, the HTM 
model facilitates the analysis of antibody-based and 
immunomodulatory tumor treatments under unique 
“human-like conditions.” We utilized two HER2 
overexpressing BC cell lines and generated a BT474- and 
a SK-BR-3- based TM (w/o a human immune system) 
and HTM (humanized with hematopoietic stem cells), 
in which solid tumor growth and tumor cell effusion 
developed, respectively. Trastuzumab treatment efficiency 
was assessed in the presence and absence of IL-15, and as 
a function of FcgRIIIa polymorphism.
Trastuzumab-treated BT474-based HTM showed an 
increased OS and DFS compared to non-treated mice. In 
contrast, SK-BR-3-bearing mice were mostly trastuzumab 
insensitive which is in line with the response characteristic 
of SK-BR-3 cells in-vitro [28]. Apparently, the immune 
system enhanced the trastuzumab treatment efficiency in 
BT474 HTM. The rate of metastasis was reduced in the 
brain (SK-BR-3) and in the lung (BT474) in HTM but not 
in TM. Obviously, the success of trastuzumab treatment 
in-vivo depends on both the immediate sensitivity of the 
target cell (which is probably higher in BT474 than in SK-
BR-3) and on the antibody-triggered immune defense.
Concurrent trastuzumab and IL-15 administration 
triggered an immune response in BT474- and even in SK-
BR-3-based HTM that resulted in tumor eradication and 
caused reduced metastasis in the lung. These results stress 
the impact and the importance of immunosurveillance as 
a vital mechanism for efficient tumor cell elimination, 
especially during a therapeutic trastuzumab treatment [21]. 
However, IL-15 induced fatal side effects in both HTM 
models. More specifically, the cytokine caused a hyper 
activation of T-cells which most probably contributed to 
reduced OS of HTM. Advanced dose-finding studies using 
HTM might help to identify an IL-15 concentration that 
efficiently triggers the anti-tumor defense accompanied by 
tolerable and manageable side effects.
A strong capacity of IL-15 to stimulate T- and NK-
cells [22-23] both in-vitro and in-vivo, which is associated 
with adverse side effects in the clinical setting, has been 
previously reported [24]. Side effects (including liver 
damage) were observed even when non-receptor coupled 
IL-15 was injected, which is supposed to be less effective 
than the IL-15/IL-15 Rα complex [29-30]. Another study 
Figure 7: Influence of the FcgRIIIA genotype on NK-cell population and the overall outcome in IL-15-treated HTM. 
Illustration of OS (A) and DFS (B) of BT474 and SK-BR-3 transplanted HTM dependent on the hetero (V/F) or homozygous (F/F) 
low affinity FcgRIIIA genotype. Numbers of analyzed animals are indicated in brackets. Significance was calculated using the Log-
rank (Mantel-Cox) test. Flow cytometric analyses of the overall percentage (C) and the percentage of CD27 expression (D) of NK-cells 
(Nkp46+) in the spleen, bone marrow (bm), lung and liver of treated and untreated HTM. Differences were calculated using two-way Anova 
(A****=p<0.0001) and Tukey’s multiple comparison test (*=p<0.05; **=p<0.01). Bars represent the mean +/- SEM and each symbol 
represents one single animal.
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performed with C57BL/6 mice and using murine IL-
15/IL-15 Rα complex revealed the immunotoxicity of 
systemic IL-15 as well [31]. Notably, the mice displayed 
extravasation of immune cells into the liver which 
apparently caused an increased liver damage (AST/ALT) 
and enhanced mortality. Noteworthy is that preclinical 
safety trials in rhesus macaque [25] failed to identify any 
side effects linked to IL-15 administration, even at high 
dosages. This phenomenon impressively demonstrates that 
safety studies conducted in primates cannot be directly 
transferred to the clinical situation. In this respect, NSG 
mice with a human immune system (HTM) might close 
the gap between pure murine based in-vivo studies and the 
clinical setting.
Trastuzumab opsonization of target cells is thought 
to trigger FcγRIIIa-(CD16)-expressing NK-cells. Hence, 
ADCC is assumed to generally contribute to tumor cell 
eradication. However, three genomic polymorphisms of 
the Fc-recognizing receptor have been identified which 
encode receptor variants characterized by homozygous 
high (V/V), heterozygous high (V/F), and homozygous 
low (F/F) affinity [32]. On the one hand, there is some 
evidence for a higher treatment efficiency of e.g., rituximab 
against Non-Hodgkin-Lymphomas in the presence of 
the high affinity V/V FcγRIIIa [33]. On the other hand, 
a more recent study reported no association between 
FcγRIIIa polymorphism and the clinical outcome [34]. 
The impact of FcγRIIIa variants in trastuzumab treated 
patients is still being debated. Only very few analyses 
have indicated that immune effector cells expressing the 
high affinity variant (V/V) of the FcγRIIIa allele mediate 
ADCC of anti-HER2 IgG1 variants better than cells 
expressing the phenylalanine encoding allele [35]. To the 
best of our knowledge, there is only one clinical study 
[36] indicating a correlation between improved outcome 
and the expression of the high affinity phenotype (V/V). 
However, a number of other communications taken from 
the clinical setting did not corroborate this relationship 
[37-39]. In fact, there is an ex-vivo ADCC study indicating 
a treatment benefit for metastatic patients in the presence 
of phenylalanine expression [40].
Trastuzumab treatment of HTM results in a 
prolonged DFS (but not OS) in heterozygous (V/F) high 
affinity- compared to homozygous low affinity-bearing 
mice. This finding is substantiated by an increased NK-cell 
number and elevated CD16 expression in heterozygous 
animals. Consequently, trastuzumab apparently causes 
enhanced ADCC only in the “high affinity setting.”
Notably, tumor cell eradication in trastuzumab/
IL-15-treated HTM is not only achieved by NK-cell 
activation but also by a stimulation and increased 
infiltration of CD33+ myeloid cells (e.g., macrophages). 
A trastuzumab-induced tumor infiltration by macrophages 
with phagocytotic activity has been recently demonstrated 
by Shi et al. [41]. The importance of anti-tumor activity 
in myeloid cells has been explicitly shown by a depletion 
of macrophages, which resulted in reduced anti-tumor-
efficacy in mouse xenograft tumor models.
Noteworthy, IL-15 treatment ended up in the 
most severe disease progression in the presence of low 
affinity FcγRIIIa variants, and triggered NK-cells more 
efficiently than in the high affinity carriers. Nevertheless, 
tumor elimination after immune modulation seems to 
be accomplished by a complex and well-orchestrated 
response that involves a variety of immune cells (e.g., 
NK-, T-, and myeloid cells) but does not depend on 
efficient ADCC alone. For example, IL-15 treatment 
in HTM caused T-cell activation and tumor eradication 
(reduced tumor volume in BT474; reduced tumor cell 
count in SK-BR-3) irrespective of the presence of “low” 
or “high affinity Fc-receptor cells.”
Besides primary tumor growth, a fatal event of 
tumor progression is tumor cell dissemination into the 
bm, which is considered to be a metastasis preceding 
process. On a related note, we addressed the question of 
whether trastuzumab treatment prevents dissemination 
or eliminates DTCs from the bm. Notably, antibody 
treatment alone did not reduce the bm tumor load in either 
HTM or TM. In contrast, the combined administration 
of trastuzumab and IL-15, which leads to immune 
cell activation as described above, tends to diminish 
the frequency of DTCs in the bm niche. An IL-15-
based immune therapy apparently reduces tumor cell 
dissemination, or enhances the elimination of already 
disseminated (dormant) DTCs, which are probably barely 
affected by conventional cytotoxic treatments or by 
irradiation.
Finally, we investigated to what extent 
disseminated tumor cells in HTM switch their phenotype 
and thereby develop trastuzumab insensitivity. In some 
SK-BR-3-transplanted mice we found DTCs in the 
bm that showed decreased CD24 and increased CD44 
expression compared to the original cells (i.e., solid 
tumor cells or non transplanted SK-BR-3 cells). In 
contrast to never transplanted, original SK-BR-3 cells, 
these CD24low/CD44high cells became insensitive to 
trastuzumab treatment. An enhanced CD44 expression 
has already been associated with trastuzumab resistance 
[42-43]. However, its importance as an indicator 
for tumor stemness is still being debated [44-45]. 
Interestingly, the development of trastuzumab resistance 
and CD44 upregulation in DTCs was independent of 
prior trastuzumab treatment and the presence of an 
immune system (i.e., immune surveillance). Notably, not 
all bm cultures with enhanced CD44 expression became 
trastuzumab resistant, which indicates that increased 
CD44 expression is somehow associated with, but not 
solely sufficient for the development of trastuzumab 
resistance. Thus, elevated CD44 expression in tumor 
cells in HTM and TM is linked to dissemination / 
metastases but not necessarily to trastuzumab resistance.
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Overall we elucidated the importance of a human 
immune response for an efficient trastuzumab treatment 
in HTM, an association of tumor cell phenotype to 
treatment response, and the power and peril of IL-15 as 
an immunotherapeutic add-on in cancer. Speculatively, an 
optimized concentration or a local accumulation of IL-15 
by using antibody drug conjugate (ADC) could utilize the 
beneficial therapeutic capacity without causing serious 
side effects.
MATERIAL AND METHODS
Breast cancer cell lines
BT474 (isolated by Lasfargues and Coutinho; ATCC 
number HTB-20) or SK-BR-3 (isolated by Trempe and 
Old; ATCC number HTB-30) breast cancer cells were used 
for cotransplantation.
Mice
Humanized tumor mice were generated as 
previously described [23]. Briefly, NOD-scid IL2Rγnull 
(NSG) mice were obtained from Jackson Laboratories 
and housed in a specialized pathogen-free facility at 
the University of Regensburg. Newborn animals were 
irradiated (1 Gy) during the first 48 hours of life and 3 
hours later transplanted with 2.5x105 human CD34+ cells 
isolated from umbilical cord blood (CB) together with 
3x106 BT474 or SK-BR-3 tumor cells in the liver.
Ethic statements
The animal work was approved by the local 
veterinary authorities of the district government based on 
the European guidelines and national regulations of the 
German Animal Protection Act (approval no. 54-2532.1-
27/11).
Cord blood samples were taken with approval from 
the Ethics Committee of the University of Regensburg 
(permission no. 11-101-0287). All patients included in the 
study provided written informed consent.
Trastuzumab +/- IL-15R-alpha complex 
preparation and treatment
BT474 (age 11 weeks) and SK-BR-3 (age 9 weeks) 
received 20µg/kg of trastuzumab (Roche Diagnostics, 
Penzberg, Germany) i.p. every week. IL-15 treatment 
was performed every second week i.p. (2.5 µg of IL-15/
IL-15Ra/Fc complex i.p. in 200 µl of PBS) using human 
recombinant IL-15 and a recombinant fusion protein 
consisting of the ectodomain of the human IL-15 receptor-
alpha-chain and the human IgG1 Fc (IL-15Ra/Fc; R&D 
Systems, Minneapolis, USA). The IL-15/IL-15Ra/Fc 
complex was prepared as previously described [23].
Mononuclear cell isolation from different tissues
Mononuclear cells were isolated from different 
mouse tissues as previously described [23]. Briefly, spleen, 
peritoneal effusion cells (PEC), lung, and liver cells were 
passed through 40 µm cell strainer (BD Bioscience, USA). 
Lung and liver cells were resuspended in 5 ml of 40% 
Percoll/RPMI, underlaid with 5 ml 70% Percoll/RPMI and 
centrifuged for 20 minutes at 800 x g. Cells were collected 
from the interface and washed twice. PEC were harvested 
from the peritoneum after cervical dislocation using 10 ml 
PBS for perfusion. To collect bone marrow cells, femurs 
were removed, ends were clipped off and rinsed with 20 
ml PBS + 2 mM EDTA using a syringe with a 27 G needle 
(BD Bioscience, Franklin Lakes, NJ, USA). The resulting 
MNC suspensions were characterized by flow cytometry 
or cultured (bone marrow).
FcgRIIIa-158V-F polymorphism genotyping
Genomic DNA was extracted using QIAamp® DNA 
Mini and Blood Mini Kit (Qiagen, Hilden, Germany) and 
the DNA concentrations were measured using a NanoDrop 
Spectrophotometer ND-1000 (peqLab Biotechnologie, 
Erlangen, Germany). For genotype analyses, DNA 
samples were diluted in nuclease-free water to reach a 
final concentration of 2.5 ng/µl.
Samples were genotyped as published previously by 
Wu et al. [46] but adapted to enhance FcgRIIIa specificity 
(e.g. new forward primer (PCR1) was designed). The 
following primers were used in nested PCR 1 (N1_
forward_new: 5’- TAA ATT ACT TGG TGA CAT GAT 
CG-3’; N1_reverse: 5’- CAG TTG GTA CCC AGG 
TTG AA-3’) and nested PCR 2 (N2_forward: 5’- ATC 
AGA TTC GAT CCT ACT TCT GCA GGG GGC AT-
3’; N2_reverse: 5’- ACG TGC TGA GCT TGA GTG 
ATG GTG ATG TTC AC-3’). The first PCR cycles for 
the nested PCR1 consisted of 5 minutes denaturation, 
1½ minutes primer annealing at 56°C, and 2 minutes 
elongation at 72°C. This was followed by 35 cycles of a 
reduced denaturation time of 1 minute, and a final cycle 
of 8 minutes elongation time at 72°C. The cycles for the 
second nested PCR were identically performed as nested 
PCR1 but with one minute annealing time at 64°C and one 
minute of elongation at 72°C.
PCR was performed using GoTaq® Colorless 
Master Mix (Promega, Mannheim, Germany) and the PCR 
product was digested with Fast Digest Hin1 II (Thermo 
Fisher Scientific, Bremen, Germany) for 15 minutes at 
37°C and subsequently heat inactivated for 5 minutes at 
80°C. Three DNA samples representing FcgRIIIa-158V/V, 
V/F and F/F genotypes were kindly provided by Dr. 
Anja Lux (Institute of Genetics, Department of Biology, 
University of Erlangen-Nuremberg, Germany), and were 
used to establish the PCR and included in each PCR run 
as an internal control. The product was analyzed on a 
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5.0% sieve agarose gel (Biozym, Oldendorf, Germany) 
including the GelRed Nucleic Acid Stain (Biotium, 
Cologne, Germany).
Flow cytometry analysis
The characterization of human immune cells and 
tumor cells was performed by flow cytometry using a 
FACSCanto-II flow cytometer which was run by Diva 
software (Ver. 7.0, BD Biosciences, San Jose, CA, USA). 
Samples were stained using the following antibodies: anti-
CD3-FITC (clone HIT3a), anti-CD19-PE (clone HIB19), 
anti-CD33-PerCP-Cy5.5 (clone P67.6), anti-CD45-APC 
(clone HI30), anti-CD56-V450 (clone B159), anti-Nkp46-
APC (clone 9E2/Nkp46), anti-CD4 FITC (clone SK3), 
anti-CD8-PE (clone HIT8a), and anti-HER2-PE (clone 
Neu 24.7) from BD Biosciences; anti-CD27 PeCy7 (clone 
O323) from eBioscience (Frankfurt, Germany); anti-
CD16 PE (clone 368), anti-CD24 AF647 (clone ML5), 
anti-CD44 AF488 (clone IM7), and anti-EpCAM BV421 
(clone 9C4) from BD BioLegend (San Diego, CA, USA). 
Appropriate mouse immunoglobulin antibodies were used 
as isotype controls for all stainings.
Immunohistochemistry and imaging
Tissue samples of spleen, liver, lung, brain and 
tumor were fixed in 4% formalin, embedded in paraffin 
and stained as previously described [29].
The following antibodies from the ultraView 
Universal DAB Detection Kit (Ventana, Roche) were 
used for (I) the humanized mice: anti-CD4 (SP35), anti-
CD8 (SP57), anti-CD79a (SCB117), anti-CD68 (PG-
MI), as well as anti CD44 (clone DF1485; Dako) and 
polyclonal rabbit anti HER2 (order number A0485, Dako). 
All antibodies were tested for specificity using tumor 
mice without human immune cells and humanized mice 
without co-transplanted tumor cells. In general the same 
positive controls as used in routine diagnostics were also 
used for this study. Histological specimens were imaged 
with an AxioImager Z1 microscope (Zeiss, Oberkochen, 
Germany).
Bone marrow cell culture and flow cytometric 
cell cycle analysis
For enrichment of the low number of cancer cells 
in organs of HTM and TM, single cell suspensions from 
bone marrow were cultured in RPMI Medium 1640, and 
supplemented with 10% fetal calf serum and antibiotics 
(100 units/ml penicillin, 100 μg/ml streptomycin). 
Cells were harvested after cell expansion (2-14 weeks) 
by trypsination and analyzed by flow cytometry. For 
trastuzumab resistance studies, cells were plated for 
ninety-six hours in 6-well plates, treated for 48 hours 
with 5 µg/ml trastuzumab (Roche Diagnostics, Penzberg, 
Germany) and the proliferation capacity was analyzed as 
follows: Harvested cells were washed twice with ice-cold 
PBS containing 2% FCS, then fixed and permeabilized 
with 70% methanol on ice over night. Finally, cells were 
washed twice with PBS and incubated in the presence 
of 10 µg/ml RNAse for 30 minutes at 37°C. The DNA 
intercalating 4′,6-Diamidin-2-phenylindol (DAPI) 
fluorochrome was added at a final concentration of 1 μg/
ml 15 min prior to analysis to ensure quantitative DNA 
staining. The DNA dye DAPI was excited with the violet 
excitation line and fluorescence emission was detected by 
the optical trigon unit equipped with a 450/50 bp filter. 
3x105 DAPI stained cells of every sample were collected. 
DNA histograms were plotted on a linear scale upon 
cell doublet, aggregate, and debris discrimination via 
pulse processing. Cell cycle fractions, i.e., percentages 
of cells in G0/G1-, S- and G2/M-phase, were quantified 
using ModFit LT 3.2 software (Verity Software House, 
Topsham, ME, USA). Treatment effects are expressed 
by the reduction in the S-phase fraction compared to 
untreated cells.
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